| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy MH Kang, CP Reynolds Clinical cancer research 15 (4), 1126-1132, 2009 | 1300 | 2009 |
| Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms V Sandor, S Bakke, RW Robey, MH Kang, MV Blagosklonny, J Bender, ... Clinical Cancer Research 8 (3), 718-728, 2002 | 685 | 2002 |
| Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) JM Maris, CL Morton, R Gorlick, EA Kolb, R Lock, H Carol, ST Keir, ... Pediatric blood & cancer 55 (1), 26-34, 2010 | 263 | 2010 |
| A phase I trial of depsipeptide (FR901228) in patients with advanced cancer JL Marshall, N Rizvi, J Kauh, W Dahut, M Figuera, MH Kang, WD Figg, ... Journal of Experimental Therapeutics and Oncology 2 (6), 325-332, 2002 | 256 | 2002 |
| Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo MH Kang, YH Kang, B Szymanska, U Wilczynska-Kalak, MA Sheard, ... Blood, The Journal of the American Society of Hematology 110 (6), 2057-2066, 2007 | 184 | 2007 |
| DNA-PK as an emerging therapeutic target in cancer IS Mohiuddin, MH Kang Frontiers in oncology 9, 635, 2019 | 171 | 2019 |
| Role of OCT4 in cancer stem-like cells and chemotherapy resistance IS Mohiuddin, SJ Wei, MH Kang Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1866 (4), 165432, 2020 | 142 | 2020 |
| Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation MH Kang, Z Wan, YH Kang, R Sposto, CP Reynolds Journal of the National Cancer Institute 100 (8), 580-595, 2008 | 135 | 2008 |
| The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma A Tagde, H Singh, MH Kang, CP Reynolds Blood cancer journal 4 (7), e229-e229, 2014 | 130 | 2014 |
| Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program MA Smith, CP Reynolds, MH Kang, EA Kolb, R Gorlick, H Carol, RB Lock, ... Clinical Cancer Research 21 (4), 819-832, 2015 | 126 | 2015 |
| Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the Pediatric Preclinical Testing Program PJ Houghton, CL Morton, R Gorlick, EA Kolb, ST Keir, CP Reynolds, ... Pediatric blood & cancer 54 (7), 921-926, 2010 | 118 | 2010 |
| Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833 I Chico, MH Kang, R Bergan, J Abraham, S Bakke, B Meadows, A Rutt, ... Journal of clinical oncology 19 (3), 832-842, 2001 | 116 | 2001 |
| A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar) S Bates, M Kang, B Meadows, S Bakke, P Choyke, M Merino, B Goldspiel, ... Cancer 92 (6), 1577-1590, 2001 | 115 | 2001 |
| Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program PJ Houghton, CL Morton, R Gorlick, RB Lock, H Carol, CP Reynolds, ... Molecular cancer therapeutics 9 (1), 101-112, 2010 | 109 | 2010 |
| Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer H Carol, I Boehm, CP Reynolds, MH Kang, JM Maris, CL Morton, ... Cancer chemotherapy and pharmacology 68, 1291-1304, 2011 | 104 | 2011 |
| Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression MH Kang, J Wang, MR Makena, JS Lee, N Paz, CP Hall, MM Song, ... Clinical Cancer Research 21 (5), 1139-1150, 2015 | 101 | 2015 |
| Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program PJ Houghton, MH Kang, CP Reynolds, CL Morton, EA Kolb, R Gorlick, ... Pediatric blood & cancer 58 (4), 636-639, 2012 | 100 | 2012 |
| Reversal of multidrug resistance: lessons from clinical oncology SE Bates, C Chen, R Robey, M Kang, WD Figg, T Fojo Mechanisms of Drug Resistance in Epilepsy: Novartis Foundation Symposium 243 …, 2002 | 100 | 2002 |
| Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program EA Kolb, R Gorlick, CP Reynolds, MH Kang, H Carol, R Lock, ST Keir, ... Pediatric blood & cancer 60 (8), 1325-1332, 2013 | 95 | 2013 |
| National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing MH Kang, MA Smith, CL Morton, N Keshelava, PJ Houghton, ... Pediatric blood & cancer 56 (2), 239-249, 2011 | 95 | 2011 |
C Patrick ReynoldsCancer Center Director, TTUHSC School of MedicineVerified email at ttuhsc.edu
